Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer.
MetadataShow full item record
<h4>Background</h4>We aimed to understand the dependence of MEK and m-TOR inhibition in EGFR(WT)/ALK(non-rearranged) NSCLC cell lines.<h4>Methods</h4>In a panel of KRAS(M) and KRAS(WT) NSCLC cell lines, we determined growth inhibition (GI) following maximal reduction in p-ERK and p-S6RP caused by trametinib (MEK inhibitor) and AZD2014 (m-TOR inhibitor), respectively.<h4>Results</h4>GI caused by maximal m-TOR inhibition was significantly greater than GI caused by maximal MEK inhibition in the cell line panel (52% vs 18%, P<10(-4)). There was no significant difference in GI caused by maximal m-TOR compared with maximal m-TOR+MEK inhibition. However, GI caused by the combination was significantly greater in the KRAS(M) cell lines (79% vs 61%, P=0.017).<h4>Conclusions</h4>m-TOR inhibition was more critical to GI than MEK inhibition in EGFR(WT)/ALK(non-rearranged) NSCLC cells. The combination of MEK and m-TOR inhibition was most effective in KRAS(M) cells.
The Institute of Cancer Research (Grant ID: Unspecified)
Version of record
Cell Line, Tumor
Carcinoma, Non-Small-Cell Lung
MAP Kinase Kinase Kinases
TOR Serine-Threonine Kinases
Clinical Pharmacology – Adaptive Therapy
Medicine Drug Development Unit (de Bono)
License start date
British journal of cancer, 2016, 115 (5), pp. 549 - 552